|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Syros Pharmaceuticals, Inc. (SYRS) |
|
|
$0.03 0.00 (3.10%) as of 4:30 Fri 6/27
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
56,200,000 |
| Market
Cap: |
1.68(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.02 - $6.53 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicines. Co.'s primary product candidates are: Tamibarotene, which is a selective retinoic acid receptor alpha agonist that is being evaluated in combination with azacitidine; SY-2101, which is an oral form of arsenic trioxide; and SY-5609, which is a selective oral inhibitor of cyclin-dependent kinase 7 that is being evaluated in combination with chemotherapy in relapsed/refractory metastatic pancreatic cancer patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
200,000 |
1,104,977 |
| Total Buy Value |
$0 |
$0 |
$321,920 |
$4,321,918 |
| Total People Bought |
0 |
0 |
2 |
3 |
| Total Buy Transactions |
0 |
0 |
5 |
6 |
| Total Shares Sold |
0 |
0 |
574,109 |
605,321 |
| Total Sell Value |
$0 |
$0 |
$300,684 |
$440,555 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
8 |
14 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Simonian Nancy A |
|
– • – |
2024-12-02 |
4 |
S |
$0.27 |
$10,016 |
D/D |
(37,070) |
4,000 |
|
91% |
|
| Simonian Nancy A |
|
– • – |
2024-11-25 |
4 |
S |
$0.27 |
$35,739 |
D/D |
(134,713) |
41,070 |
|
91% |
|
| Quirk Gerald E |
Chief Legal & Compliance Offic |
• – – |
2024-11-19 |
4 |
S |
$0.22 |
$10,321 |
D/D |
(46,657) |
0 |
|
91% |
|
| Roth David |
Chief Medical Officer |
• – – |
2024-11-18 |
4 |
S |
$0.20 |
$2,382 |
D/D |
(12,099) |
0 |
|
87% |
|
| Stephens Kristin |
Chief Development Officer |
• – – |
2024-11-18 |
4 |
S |
$0.22 |
$7,949 |
D/D |
(36,133) |
0 |
|
87% |
|
| Haas Jason |
Chief Financial Officer |
• – – |
2024-11-18 |
4 |
S |
$0.21 |
$28,980 |
D/D |
(137,803) |
0 |
|
87% |
|
| Chee Conley |
President & CEO |
• • – |
2024-11-18 |
4 |
S |
$0.20 |
$26,932 |
D/D |
(134,797) |
0 |
|
87% |
|
| Simonian Nancy A |
|
– • – |
2024-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
40,125 |
175,783 |
|
- |
|
| Chee Conley |
President & CEO |
• • – |
2024-10-31 |
4 |
D |
$2.09 |
$18,198 |
D/D |
(8,707) |
130,797 |
|
- |
|
| Chee Conley |
President & CEO |
• • – |
2024-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,000 |
139,504 |
|
- |
|
| Stephens Kristin |
Chief Development Officer |
• – – |
2024-10-31 |
4 |
D |
$2.09 |
$12,757 |
D/D |
(6,104) |
36,133 |
|
- |
|
| Stephens Kristin |
Chief Development Officer |
• – – |
2024-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,000 |
42,237 |
|
- |
|
| Haas Jason |
Chief Financial Officer |
• – – |
2024-10-31 |
4 |
D |
$2.09 |
$11,754 |
D/D |
(5,624) |
137,803 |
|
- |
|
| Haas Jason |
Chief Financial Officer |
• – – |
2024-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,875 |
143,427 |
|
- |
|
| Roth David |
Chief Medical Officer |
• – – |
2024-10-31 |
4 |
D |
$2.09 |
$14,162 |
D/D |
(6,776) |
12,099 |
|
- |
|
| Roth David |
Chief Medical Officer |
• – – |
2024-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,875 |
18,875 |
|
- |
|
| Quirk Gerald E |
Chief Legal & Compliance Offic |
• – – |
2024-09-30 |
4 |
D |
$2.10 |
$6,510 |
D/D |
(3,100) |
46,657 |
|
- |
|
| Quirk Gerald E |
Chief Legal & Compliance Offic |
• – – |
2024-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
49,757 |
|
- |
|
| Young Richard A |
|
– • – |
2024-09-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,667 |
10,667 |
|
- |
|
| Akkaraju Srinivas |
|
– • – |
2024-09-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,667 |
9,333 |
|
- |
|
| Haas Jason |
Chief Financial Officer |
• – – |
2024-09-12 |
4 |
B |
$1.68 |
$76,006 |
D/D |
45,344 |
124,552 |
0.01 |
-87% |
|
| Chee Conley |
President & CEO |
• • – |
2024-09-11 |
4 |
B |
$1.71 |
$85,420 |
D/D |
50,000 |
122,504 |
0.01 |
-87% |
|
| Haas Jason |
Chief Financial Officer |
• – – |
2024-09-11 |
4 |
B |
$1.58 |
$30,446 |
D/D |
19,293 |
79,208 |
0.01 |
-87% |
|
| Chee Conley |
President & CEO |
• • – |
2024-09-10 |
4 |
B |
$1.51 |
$75,260 |
D/D |
50,000 |
72,504 |
0.01 |
-87% |
|
| Haas Jason |
Chief Financial Officer |
• – – |
2024-09-10 |
4 |
B |
$1.55 |
$54,788 |
D/D |
35,363 |
59,915 |
0.01 |
-87% |
|
192 Records found
|
|
Page 1 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
